Antidote Therapeutics, Inc.

Antidote Therapeutics, Inc. is a biopharmaceutical company developing drugs for treating diseases caused or worsened by nicotine. Antidote’s portfolio offers unique first-in-class approach to block nicotine’s harmful effects on the brain and other organs: • Fully human, anti-nicotine monoclonal antibody (ATI-1013) • Nicotine-degrading enzyme (ATI-3009) Unlike current FDA-approved smoking cessation treatments, Antidote’s candidates do not contain nicotine or interact with nicotine-receptors in the brain or body. Instead, our drugs are designed to trap or eliminate nicotine in the blood, having the dual benefit of 1) neutralizing nicotine’s direct, harmful effects on organs throughout the body and 2) preventing nicotine from reaching the brain, reducing the addictiveness of nicotine from cigarettes, e-cigarettes, and smokeless tobacco. Antidote’s innovative development strategy (focused on treating existing disease to improve medical outcomes rather than preventing future smoking-related illnesses that may occur decades later) is significantly different from how other drugs that target nicotine’s actions have been developed as aids to smoking cessation. The first indications for Antidote’s anti-nicotine drugs are the treatment of orphan vascular diseases in smokers where nicotine plays an important role in causing disease progression, such as Buerger’s Disease and Critical Limb Ischemia. Our products, which neutralize nicotine’s direct cardiovascular effects, may also help patients quit or substantially reduce smoking. This is expected to lead to better overall treatment outcomes across all vascular disease patients. In the future, we plan to expand the uses of our products to other smoking-related illnesses where blocking nicotine’s effects will have near-term medical benefit as well as a general aid to smoking cessation.